These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36222298)

  • 1. Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS‑mutated lung cancer cells.
    Wang M; Chen X; Fu G; Ge M
    Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36222298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma.
    Du H; Chen B; Jiao NL; Liu YH; Sun SY; Zhang YW
    Oxid Med Cell Longev; 2020; 2020():7370157. PubMed ID: 32215178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione Peroxidase 1 Promotes NSCLC Resistance to Cisplatin via ROS-Induced Activation of PI3K/AKT Pathway.
    Chen B; Shen Z; Wu D; Xie X; Xu X; Lv L; Dai H; Chen J; Gan X
    Biomed Res Int; 2019; 2019():7640547. PubMed ID: 31032363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
    Shao N; Song L; Sun X
    Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
    Shen Q; Xu Z; Xu S
    Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
    Caiola E; Salles D; Frapolli R; Lupi M; Rotella G; Ronchi A; Garassino MC; Mattschas N; Colavecchio S; Broggini M; Wiesmüller L; Marabese M
    Oncotarget; 2015 Oct; 6(30):30072-87. PubMed ID: 26353932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
    Xie H; Yao J; Wang Y; Ni B
    Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.
    Gu L; Deng ZJ; Roy S; Hammond PT
    Clin Cancer Res; 2017 Dec; 23(23):7312-7323. PubMed ID: 28912139
    [No Abstract]   [Full Text] [Related]  

  • 13. Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p.
    Luo S; Shen M; Chen H; Li W; Chen C
    Mol Med Rep; 2020 Nov; 22(5):3822-3832. PubMed ID: 32901838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
    Zhu C; Jiang X; Xiao H; Guan J
    Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis.
    Yan WY; Cai J; Wang JN; Gong YS; Ding XB
    Neoplasma; 2022 May; 69(3):648-656. PubMed ID: 35330996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
    Liu Y; Zhang Y; Li Q; Xu R; Huang N
    Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of METTL14-mediated m
    Gong S; Wang S; Shao M
    J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
    Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
    Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.
    Shin DH; Jo JY; Choi M; Kim KH; Bae YK; Kim SS
    Exp Mol Med; 2023 Oct; 55(10):2220-2237. PubMed ID: 37779142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.